8-K: Protagenic Therapeutics Faces Nasdaq Delisting Notice After Failing to Regain Minimum Bid Price Compliance

Protagenic Therapeutics received a delisting notice from Nasdaq after failing to meet the minimum bid price requirement, but the company's securities remain listed pending a hearing.

Summary

• Protagenic Therapeutics, Inc. received a notification from Nasdaq on January 22, 2025, stating that it has not regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires maintaining a minimum bid price of $1.00 per share.
• The company was initially notified of non-compliance on July 24, 2024, and was given 180 days to regain compliance, which expired on January 21, 2025.
• Protagenic Therapeutics is not eligible for a second 180-day compliance period because it does not meet the requirements for initial listing on The Nasdaq Capital Market.
• The delisting notice does not immediately affect the listing of the company's securities on the Nasdaq Capital Market.
• The company will address this matter in its presentation to the Nasdaq Hearings Panel on January 30, 2025.
• Protagenic Therapeutics remains focused on meeting all listing requirements.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice, indicating potential financial and operational challenges for the company. However, the fact that the listing is not immediately affected and the company is focused on compliance provides a slight buffer.

Positives

• The notification letter has no immediate effect on the listing of the company's securities on the Nasdaq Capital Market.
• The company remains focused on meeting all listing requirements.

Negatives

• Protagenic Therapeutics failed to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• The company is not eligible for a second 180-day compliance period.
• The company received a delisting notice from Nasdaq.

Risks

• The company faces the risk of being delisted from the Nasdaq Capital Market if it cannot convince the Nasdaq Hearings Panel to grant an exception.
• Failure to maintain listing could negatively impact investor confidence and the company's ability to raise capital.

Future Outlook

The company will present its case to the Nasdaq Hearings Panel on January 30, 2025, and remains focused on meeting all listing requirements.

Management Comments

• The company remains focused on meeting all listing requirements in the normal course of business.

Industry Context

Many small-cap biotech companies struggle to maintain the minimum bid price required for Nasdaq listing, especially during periods of market volatility or when facing challenges in their drug development programs. Delisting can significantly impact a company's access to capital and investor confidence.

Comparison to Industry Standards

• Other biotech companies facing similar delisting notices often explore options such as reverse stock splits to increase their share price and regain compliance.
• Companies like Geron Corporation have successfully navigated similar situations by demonstrating progress in their clinical trials and securing financing.
• However, companies like Agenus Inc. have faced delisting challenges despite promising clinical data, highlighting the importance of market sentiment and financial stability.

Stakeholder Impact

• Shareholders face the risk of potential delisting, which could negatively impact the value of their investment.
• Employees may experience uncertainty regarding the company's future prospects.
• The company's ability to raise capital and fund its operations could be affected.

Next Steps

• Protagenic Therapeutics will present its case to the Nasdaq Hearings Panel on January 30, 2025.
• The company will continue to focus on meeting all listing requirements.

Key Dates